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Adjunctive quetiapine for serotonin reuptake
inhibitor-resistant obsessive–compulsive disorder:
a meta-analysis of randomized controlled treatment trials
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Thanusha Sivakumarana, Bavanisha Vythilingumf, Soraya Seedatf,
Herman Westenbergg and Damiaan Denysg
Small studies have shown positive effects from adding
a variety of antipsychotic agents in patients with
obsessive–compulsive disorder who are unresponsive to
treatment with serotonin reuptake inhibitors. The evidence,
however, is contradictory. This paper reports a
meta-analysis of existing double-blind randomized
placebo-controlled studies looking at the addition of the
second-generation antipsychotic quetiapine in such cases.
Three studies fulfilled the inclusion criteria. Altogether 102
individuals were subjected to analysis using Review
Manager (4.2.7). The results showed evidence of efficacy
for adjunctive quetiapine (< 400mg/day) on the primary
efficacy criterion, measured as changes from baseline in
total Yale–Brown Obsessive Compulsive Scale scores
(P=0.008), the clinical significance of which was limited
by between-study heterogeneity. The mechanism
underlying the effect may involve serotonin and/or
dopamine neurotransmission. Int Clin Psychopharmacol
21:337–343 c 2006 Lippincott Williams & Wilkins.
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Introduction
Although serotonin reuptake inhibitors (SRIs) effect
satisfactory improvements in obsessive–compulsive dis-
order (OCD) for many individuals, residual symptoms
remain. Even after switching to a second SRI, approxi-
mately 30% cases do not respond (March et al., 1997;
Eddy et al., 2004). Compared with data supporting first-
line treatments for OCD (Fineberg and Gale, 2005), the
evidence base for second-line treatments is slim and
based on small numbers of small studies. Reports on
placebo-controlled studies of SRI augmentation using
haloperidol, risperidone, olanzapine and quetiapine sup-
port further exploration of the efficacy of this approach in
resistant OCD, although negative and positive findings
have been reported (Fineberg et al., 2006).
Quetiapine, administered as an adjunct to SRIs, has been
the subject of recent investigation. The drug is reported
to be associated with a favourable adverse effect profile
compared with other second-generation antipsychotics,
with reduced propensity for extrapyramidal side effects,
prolactin and sexual dysfunction (Toren et al., 2004).
Preliminary open-label studies showed benefits in up to
50% treated cases of OCD (Denys et al., 2002; Sevincok
and Topuz, 2003; Bogan et al., 2005) although one study
showed little benefit (Mohr et al., 2002). A single-blind
study by Atmaca et al. (2002) found a clinical response in
14 of 27 (64%) cases. Three double-blind, randomized
placebo-controlled studies of quetiapine have been
recently completed and show contradictory results. In
the first, Denys et al. (2004a) showed significant and
robust efficacy for quetiapine augmentation in a sample
of 40 SRI-unresponsive cases. More recent studies,
however, by Carey et al. (2005) and Fineberg et al.
(2005), which investigated 42 and 21 individuals,
respectively, reported no statistically significant be-
tween-group differences on any of the outcome measures.
Given the relatively small effect sizes seen for quetiapine
in these studies and the variability in placebo-response
rates, it seems clear that larger randomized controlled trials
are needed to confirm efficacy. At present, the prospect of
such large-scale studies being conducted is not promising.
Meta-analyses cannot substitute for high-quality head-to-
head comparator trials but may compensate for small study
size by combining data from separate studies using specific
rules. In this paper, the authors of the three published
randomized controlled trials of adjunctive quetiapine
pooled their study data to produce the first meta-analysis
of adjunctive antipsychotic treatment for resistant OCD.
Quetiapine has a istinct pharmacological profile compared
with other second-generation antipsychotics. Therefore, it
0268-1315 c 2006 Lippincott Williams & Wilkins
was decided not to include other antipsychotic trials
within this analysis.
Method
A search of the major bibliographic databases (EMBase,
Medline, Psychinfo, Cochrane Library) confirmed the
existence of just three published double-blind placebo
controlled randomized treatment studies investigating
adjunctive quetiapine in SRI-treated cases of DSM-IV
(Diagnostic and Statistical Manual of Mental Disorders –
Fourth edition) OCD. All three studies were critically
appraised for methodological quality and fulfilled the
following criteria: double-blind random allocation, inten-
tion-to-treat analysis and the mean and standard devia-
tion for continuous outcomes reported. Outcome data
were extracted directly from the studies by one
independent reviewer (PP) and entered into Review
Manager 4.2.7 (Cochrane Collaboration, 2004). Meta-
analysis was then used to synthesize the evidence using
Review Manager. Efficacy outcomes were calculated on
an intention-to-treat basis. The following key compar-
isons between quetiapine and placebo were performed:
1. Responder rates (defined according to study criterion).
2. Changes from baseline Yale–Brown Obsessive
Compulsive Scale (Y-BOCS, Goodman et al., 1989)
total scores (chosen as the a priori primary efficacy
criterion).
3. Changes from baseline depression scores: Hamilton
Depression Scale (Ham-D, Hamilton, 1967) or
Montgomery Asberg Depression Rating Scale
(MADRS, Montgomery and Asberg, 1979).
4. Changes from baseline Sheehan Disability Scale scores
(Leon et al., 1992).
5. Number of patients leaving the study early.
6. Number of patients leaving the study early owing to
adverse events.
7. Number of serious adverse events.
Dichotomous outcomes were presented as relative risks
(RRs) (ratio of the treatment event rate to the control
event rate; an RR of 1 indicates no difference between
treatment and control) with the associated 95% confidence
interval (CI). Continuous outcomes were analysed as
standardized mean difference (SMD). To check for
heterogeneity between studies, we used w2 tests (P<0.1)
and visual inspection of the plots. If heterogeneity was
established, an attempt was made to explain the variation.
Results
Individual studies are summarized in Table 1. In the first,
Denys et al. (2004a) showed significant efficacy for
quetiapine augmentation in a sample of 40 patients who
had previously failed to respond to at least two SRIs. An
intent-to-treat analysis for the 20 quetiapine-treated
cases showed a significant advantage over placebo from
4 weeks onwards on the Y-BOCS and an average
improvement of 32% from baseline Y-BOCS scores,
compared with 6.8% improvement in the placebo group
at the 8-week endpoint. In the study by Carey et al.
(2005), 42 individuals who had responded inadequately
to open-label treatment with an SRI for 12 weeks were
randomized to either placebo or flexible doses of
quetiapine added into their treatment. Both quetiapine
and placebo-treated groups improved to a similar extent
(26.9 and 26% post-baseline reduction in Y-BOCS scores,
respectively) at the end of the 6-week treatment period.
In the study by Fineberg et al. (2005), 21 patients with
OCD who had failed to respond to at least 6 months of
SRI treatment were randomized to 16 weeks of treatment
with SRI and quetiapine or SRI and placebo. The
quetiapine group’s reduction in baseline Y-BOCS scores
averaged 13.8% at week 16 compared with 5.8% under
placebo. No statistically significant between-group differ-
ences were observed on any of the outcome scores.
The results of the meta-analysis are presented in Fig. 1 as
forest plots. Altogether, 102 cases were analysed. Each
forest plot displays the effect size and CI for each study
as well as the summary statistic. The graphs are organized
so that the display of data to the left of the ‘line of no
effect’ indicates a favourable outcome for quetiapine.
Primary outcome measure
The second forest plot (Fig. 1) shows evidence
of a clinically significant effect favouring quetiapine
Table 1 Characteristics of included studies
Study Failure to Condition Duration
(weeks)
Patients Female/
male
Age (years)
(SD)
Maximum
dose
(mg/day)
Baseline
Y-BOCS
(SD)
Endpoint
Y-BOCS
(SD)
Mean percentage
decrease in
Y-BOCS (%)
Denys et al. (2004a) 2 SRIs Placebo 8 20 14/6 34 (10) 300 26.4 (6.3) 24.6 (6.7) 6.8
Quetiapine 8 20 16/4 36 (14) 300 28.2 (4.3) 19.2 (6.4) 32
Carey et al. (2005) 1 SRI Placebo 6 21 13/8 31.8 (12.1) 300 27.7 (3.9) 20.5 26
Quetiapine 6 20 9/11 33.8 (9.7) 300 26.4 (4.6) 19.3 26.9
Fineberg et al. (2005) 1 SRI Placebo 16 10 4/6 37.9 (10.7) 400 24.1 (4.3) 22.7 (5.5) 5.8
Quetiapine 16 11 8/3 37.4 (11.4) 400 24.5 (4.6) 21.1 (6.4) 13.8
SRI, serotonin reuptake inhibitor.
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augmentation over placebo in improving obsessive–
compulsive symptoms measured as changes from baseline
in total Y-BOCS scores (P=0.008). From the three
studies (Denys et al., 2004a; Carey et al., 2005, Fineberg
et al., 2005, n=102), the SMD between the quetiapine
group and the placebo group on the change in Y-BOCS
score from baseline was statistically significant, favouring
the quetiapine group (SMD= –0.55, 95% CI, – 0.96 to
– 0.15). We cannot be confident about efficacy, however,
because the effect edges towards the ‘line of no effect’
and overlaps with the region of uncertainty. Therefore,
the result indicates ‘limited clinical significance’, that is,
a point intermediate between ‘strong’ and ‘insufficient’
clinical significance where the CI includes values other
than clinically important effects. Of the three individual
studies, only the study by Denys et al. (2004a) produced a
statistically significant result. The degree of heterogen-
eity between the studies reached statistical significance
(P=0.02). Heterogeneity was removed when the study
by Denys et al. was excluded from the analysis, suggesting
that this study was mainly responsible for the overall
effect.
Secondary outcome measures
Responder rates were defined as >35% improved
baseline Y-BOCS and ‘much’ or ‘very much improved’
on the Clinical Global Impressions Improvement Scale
(Guy, 1976) in the studies by Denys et al. (2004a) and
Carey et al. (2005), or as > 25% improved baseline
Y-BOCS in the study by Fineberg et al. (2005). From the
three studies, the number of non-responders was 32 out
of 51 patients in the quetiapine group and 38 out of
51 patients in the placebo group. The likelihood of non-
response in the quetiapine group relative to the placebo
group was not significantly different (RR=0.84, 95%
CI, 0.64 to 1.09). No evidence showed efficacy on the
meta-analysis for any of the secondary outcome measures,
apart from a significant advantage favouring quetiapine on
the Work Subscale score of the Sheehan Disability Scale
(P=0.03). From two studies (Denys et al., 2004a;
Fig. 1
43.75
21.48
,, ,,,, ,,
Forest plots showing results of the meta-analysis.
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Fineberg et al., 2005; n=61), the SMD between the
quetiapine group and the placebo group on the Sheehan
Disability Scale-Work Subscale was statistically significant
(SMD= –0.59, 95% CI, – 1.11 to – 0.07), although we
cannot be confident about the clinical significance of this
difference because the SMD approaches the ‘line of no
effect’. This effect did not, however, extend to the total
Sheehan Disability Scale score (P=0.99). From the three
studies (Denys et al., 2004a; Carey et al., 2005; Fineberg et al.,
2005), the number of participants discontinuing from the
study was four out of 51 patients in the quetiapine group
and one out of 51 in the placebo group. No significant
difference was observed between the quetiapine group and
the placebo group on the likelihood of discontinuing from
the study (RR=2.43, 53% CI, 0.5 to 11.69).
Discussion
This is the first meta-analysis to be reported and the
largest cohort of resistant cases of OCD, augmented with
antipsychotic under double-blind conditions, to have
been analysed. Notwithstanding statistical limitations,
the results of the analysis are positive and show evidence
supporting efficacy for quetiapine using the primary
efficacy criterion. To find a significant difference in
relatively small numbers suggests that the finding is
robust. Moreover, the finding of a significant difference
on one of the domains on the Sheehan Disability Scale is
an argument for clinical relevance.
Meta-analyses are subject to various methodological
shortcomings, often attributable to between-study differ-
ences that diminish the validity of combining their data
under a single analysis. In our case, the included studies
shared important features such as the diagnostic classi-
fication of cases (DSM-IV), primary efficacy parameter
and pivotal rating scales. The ages and sex ratio of the
cases and dose range of quetiapine (maximum 300mg/day
or 400mg/day) were also similar (Table 1). Clear
differences, however, were observed between the three
studies in terms of (1) entry criteria, (2) duration and
(3) sample sizes.
Fig. 1 (Continued )
heterogeneity
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Denys et al. (2004a) and Fineberg et al. (2005) excluded
comorbid axis 1 pathology including tic disorders, whereas
Carey et al. (2005) did not. In addition, Denys et al.
(2004a) and Fineberg et al. (2005) only included patients
who had failed at least 4 months before SRI treatment,
thereby limiting the sample to truly SRI-resistant cases.
This was supported by low placebo-response rates
amounting to a mean reduction of around 6% from
baseline Y-BOCS scores in both studies. In contrast,
the study by Carey et al. (2005) showed an unusually
high placebo-response rate (26%) that the authors
attributed to the possible inclusion of non-resistant cases
that went on to respond to treatment with SRI extended
beyond the 6-week entry criterion. The studies also
differed in terms of duration (see Table 1) but it is
unlikely that this would have affected the results. Most
studies have found positive effects of antipsychotic
addition develop within 4 weeks and last for several
months (Maina et al., 2003). The endpoints of our studies
at 6, 8 and 16 weeks fall within that time frame. On
the other hand, there are no controlled research trials on
the efficacy of antipsychotic addition over the long
term. Finally, there are differences with regard to sample
size. Studies of both Denys et al. (2004a) and Carey
et al. (2005) were conducted on samples comprising
40 patients, which should be sufficient to detect a mean
difference in Y-BOCS score of Z 3.6 between quetiapine
and placebo. The study by Fineberg et al. (2005)
was conducted on a smaller sample of 21 patients
which requires a mean difference in Y-BOCS scores
between quetiapine and placebo of at least 5.3 to reach a
power of 0.8.
Fig. 1 (Continued)
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Although limited, our analysis shows evidence of efficacy
for quetiapine for SRI-resistant OCD patients. The
beneficial effect of adding quetiapine to SRIs in OCD
is intriguing as it is generally accepted that antipsychotics
in monotherapy lack efficacy in OCD (McDougle et al.,
1995; Connor et al., 2005). Several possible explanations
exist for the efficacy of quetiapine addition. The first is a
pharmacokinetic interaction between quetiapine and
SRIs. Quetiapine and its metabolites are weak inhibitors
of human cytochrome P450 1A2, 2C9, 2C19, 2D6 and 3A4
enzymes, although at concentrations 10 to 50-fold higher
than used in these studies (maximum 400mg/daily).
Therefore, it is unlikely that quetiapine would enhance
the efficacy of SRIs by inhibiting their metabolism. On
the other hand, SRIs such as paroxetine, fluvoxamine and
fluoxetine might inhibit the CYP3A4 system, which is
primarily responsible for metabolizing quetiapine. Then
again, there is no evidence that higher doses of
quetiapine are more effective than lower doses in treating
OCD, although dose-ranging studies have yet to be
performed. Next, a number of pharmacodynamic hypoth-
eses may be advanced. The enhanced therapeutic
response may be caused by a specific synergistic quality
of the combination of SRIs with antipsychotics. Marek
et al. (2003), for example, suggested that the clinical
efficacy of SRIs with atypical antipsychotics resulted from
blockade of 5-HT2A coincident with activation of non-5-
HT2A serotonergic receptors. This appealing hypothesis
may account for the efficacy of risperidone, olanzapine or
quetiapine but not for the efficacy of haloperidol
(McDougle et al., 1994), which is 30-fold more potent
at the D2 than at the 5-HT2A receptor. The efficacy of
haloperidol and pimozide (McDougle et al., 1990) as
adjuncts to SRIs favours the significance of dopaminergic
antagonism. Although preliminary, preclinical studies
suggest that the combination of an SRI with an atypical
antipsychotic results in a unique synergistic effect on
extracellular dopamine levels in the prefrontal cortex. For
example, the combination of olanzapine with fluoxetine
resulted in a robust and sustained increase of extracellular
dopamine and noradrenaline levels in the prefrontal
cortex (Zhang et al., 2000). These increases were
significantly higher than the increases achieved with
either drug in monotherapy. Denys et al. (2004b) found
similar increases of extracellular dopamine levels in the
prefrontal cortex following co-administration of fluvox-
amine with quetiapine. This synergistic effect on
dopamine levels did not apply to changes in extracellular
serotonin, nor was it observed in other brain areas such as
the striatum or the nucleus accumbens. Changes in
dopamine activity within the prefrontal cortex may be
critical for OCD, as it is suggested that dopamine
coordinates the long-term extinction of fear conditioning
and modulates neural interactions between the prefrontal
cortex, hippocampus and amygdala. Further research is
needed to determine whether changes in extracellular
dopamine levels account for the clinical efficacy of
addition strategies with antipsychotic agents such as
quetiapine in treatment-resistant OCD.
Conclusions
This meta-analysis of three double-blind, randomized
placebo-controlled studies reports limited evidence of
efficacy of adjunctive quetiapine in SRI-unresponsive
cases. The mechanism underpinning the therapeutic
effect remains poorly understood and may involve
neurotransmitters other than serotonin.
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